These transcriptional changes would be validated at the protein level using CyTOF or classical flow cytometry to assess expression not only the tumor cells but also in relevant surface markers on immune cells (e.g., CD8+ T cells or dendritic cells) co-cultured with the modified cancer cells. The gene discussed is CD8A; the disease is neoplasm.